The QualityStocks Daily Tuesday, June 11th, 2024

Today's Top 3 Investment Newsletters

MarketClub Analysis(TPET) $0.3596 +56.35%

CBDWire(GTVH) $0.0022 +34.38%

Jeff Bishop(GME) $30.4900 +22.80%

The QualityStocks Daily Stock List

Know Labs Inc. (KNW)

The Stock Dork, QualityStocks and MarketBeat reported earlier on Know Labs Inc. (KNW), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Know Labs Inc. (NYSE American: KNW) is a medical device firm focused on developing and commercializing proprietary biosensor technologies.

The firm has its headquarters in Seattle, Washington and was incorporated in 1998, on October 8th by Ronald Peter Erickson. Prior to its name change in May 2018, the firm was known as Visualant Inc. It operates as part of the scientific and technical instruments industry, under the technology sector. The firm serves consumers in the United States.

The company is committed to making a difference in the lives of millions of individuals globally by developing convenient and affordable non-invasive medical diagnostics solutions.

The enterprise operates through the Development of Bio-RFID and ChromaID Technology, Particle, Technology, and AI Sales of NFT Products segments. Its proprietary platform technologies include ChromaID and Bio-RFID, which utilize electromagnetic energy along the electromagnetic spectrum to perform analytics. Bio-RFID is a non-invasive diagnostic technology platform for medical diagnostics. This platform uses electromagnetic energy and can be integrated into a variety of wearable, mobile, or bench-top form factors. The first application of its technology is a glucose monitor device, the UBAND. It will provide the user with real-time information on their blood glucose levels, assisting billions of people with diabetes and pre-diabetes to manage this medical condition.

The firm, which is set to release its latest financial results, remains focused on developing technologies that will better the lives of many while also creating value for its shareholders.

Know Labs Inc. (KNW), closed Tuesday's trading session at $0.8, up 15.9252%, on 198,978 volume. The average volume for the last 3 months is 16,266 and the stock's 52-week low/high is $0.23/$1.3418.

Elutia Inc. (ELUT)

QualityStocks and MarketBeat reported earlier on Elutia Inc. (ELUT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Elutia Inc. (NASDAQ: ELUT) is a commercial-stage biotechnology firm that is focused on the development and commercialization of drug-eluting biomatrix technology to enhance surgical outcomes.

The firm has its headquarters in Silver Spring, Maryland and was incorporated in 2015, on August 6th by Charles Randal Mills and Kevin L. Rakin. Prior to its name change in September 2023, the firm was known as Aziyo Biologics Inc. It operates as part of the medical devices industry, under the healthcare sector. The firm serves consumers across the globe.

The enterprise operates through the Device Protection, Women’s Health, Cardiovascular and Orthobiologics segments. Its product portfolio is comprised of CanGaroo, ViBone, SimpliDerm, VasCure, OsteGro V, Fiber VBM, Tyke and ProxiCor. Its CanGaroo Envelope offering is used for the stabilization of implantable cardiac devices like defibrillators and pacemakers while its CanGaroo RM offering has been designed to deliver medicine directly to the surgical site. Its SimpliDerm Acellular Dermal Matrix offering is used primarily in breast reconstruction following mastectomy. These products are primarily sold to healthcare providers or commercial partners. In device protection, it sells biological envelopes that form a natural, systemically vascularized pocket for holding implanted electronic devices. In cardiovascular, the enterprise sells its specialized porcine small intestine submucosa (SIS ECM) for use as an intracardiac and vascular patch. It also sells human tissue products under contract manufacturing and other arrangements with corporate customers.

The company recently rebranded to reflect its strategic focus on drug eluting biomatrices, a move that may increase its visibility while also opening its up to new growth and investment opportunities.

Elutia Inc. (ELUT), closed Tuesday's trading session at $3.965, up 14.2651%, on 94,129 volume. The average volume for the last 3 months is 215,382 and the stock's 52-week low/high is $1.1001/$4.3899.

Sonim Technologies (SONM)

StockEarnings, QualityStocks, MarketBeat, StocksEarning, StockMarketWatch, The Stock Dork, StockRockandRoll, PennyStockLocks, Penny Stock 101, The Online Investor and InvestorPlace reported earlier on Sonim Technologies (SONM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sonim Technologies Inc. (NASDAQ: SONM) (FRA: 2W9) is engaged in the provision of ruggedized mobile accessories and phones for task workers.

The firm is based in Austin, Texas and was incorporated in 1999 on August 5th by Joakin Wiklund, Sudu Srinivasan, Jai Kumar, Anush Gopalan, Isaac Eteminan and Ram Chandran. Prior to its name change in December 2001, the firm was known as Inc.

The company provides solutions in 3 categories namely, cloud-based software and application services; industrial-grade accessories; and, ultra-rugged mobile devices. It sells accessories, barcode scanners and ruggedized phones through distribution channels in Europe, South America and North America and sells its accessories and mobile phones primarily to wireless carriers in Canada and the U.S. It serves defense, agriculture, transportation, utilities, oil and gas, security and construction industries across the globe.

Its products include a portable communications system dubbed the Rapid Deployment Kit; hands-free in-vehicle voice communication solution, multi-bay charging accessories and remote speaker microphones, which are all industrial grade accessories and the Sonim XP3, XP5s and XP8, which are all based on the android platform and can attach to private and public wireless networks. The enterprise also offers SmartScanner products like an android-based tablet called Sonim RS80 and an LTE device that’s android-based called Sonim RS60.

The company recently entered into a partnership with Business Mobility Partners, a distributor of T-Mobile for business services and products. This move will allow business consumers for T-Mobile to access Sonim’s ultra-rugged devices, which will help extend the firm’s consumer reach and is bound to bring in more investors.

Sonim Technologies (SONM), closed Tuesday's trading session at $0.6278, up 14.1247%, on 637,529 volume. The average volume for the last 3 months is 143,560 and the stock's 52-week low/high is $0.44/$1.30.

Biodesix Inc. (BDSX)

MarketBeat, StockEarnings, QualityStocks, InsiderTrades, Top Pros' Top Picks, The Stock Dork, StreetInsider and InvestorPlace reported earlier on Biodesix Inc. (BDSX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Biodesix Inc. (NASDAQ: BDSX) is a diagnostic solutions firm that is focused on the provision of blood-based tests for various lung indications.

The firm has its headquarters in Boulder, Colorado and was incorporated in 2005 by Robert E. Cawthorn and David Brunel. Prior to its name change, the firm was known as Elston Technologies Inc. It operates as part of the scientific research and development services industry. The firm has five companies in its corporate family and serves consumers in the United States.

The company uses its artificial intelligence-based and data driven platform to discover, develop and commercialize solutions for clinically unmet needs, with a focus on the lung cancer continuum of care. It derives its revenue from offering biopharmaceutical firms with services that are provided outside the clinical setting; developing and commercializing companion diagnostics; and offering diagnostic testing associated with coronavirus tests and blood-based lung tests.

The enterprise’s products include a serum proteomic test dubbed VeriStrat, which offers predictive and prognostic information for non-small cell lung cancer patients; a genomic blood test known as GeneStrat, indicated for use in patients with advanced lung cancer; and the Bio-Rad ddPCR test, which has been developed to detect the presence of infection by the SARS-CoV-2 virus.

The company recently announced its latest financial results for 2021 which show growth of its core biopharma and lung diagnostics product offerings. It expects this growth to continue in 2022, driven by the growing body of clinical evidence which supports the value of the company’s tests. This growth not only brings in more revenues into the company but will also positively influence investments into the firm.

Biodesix Inc. (BDSX), closed Tuesday's trading session at $1.55, up 11.5108%, on 279,687 volume. The average volume for the last 3 months is 1.373M and the stock's 52-week low/high is $1.03/$2.21.

GT Biopharma Inc. (GTBP)

QualityStocks, MarketBeat, StocksEarning, InvestorPlace, StockWireNews, PoliticsAndMyPortfolio, Penny Stocks Profile, MarketClub Analysis and Fierce Analyst reported earlier on GT Biopharma Inc. (GTBP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GT Biopharma Inc. (NASDAQ: GTBP) (FRA: OXI) is a biopharmaceutical firm that is engaged in developing and commercializing of immune-oncology products based off of its TriKE fusion protein cell engager technology platform.

The firm has its headquarters in Beverly Hills, California and was incorporated in 1965. Prior to its name change in July 2017, the firm was known as Oxis International Inc. The firm serves consumers around the globe.

The company is party to a collaboration agreement with Cytovance Biologics which entails the provision of development services for a TriKE therapeutic for treating the coronavirus infection; and a license agreement with the Regents of the University of Minnesota which involves the development and commercialization of cancer therapies through the use of TriKE technology. It is also party to a development partnership agreement with Altor BioScience Corp., for the development of a TriKE (Tri-specific Killer Engager) fusion protein for cancer therapies.

The enterprise’s product pipeline comprises of a scFv recombinant fusion protein conjugate dubbed GTB-4550, developed to treat PD-L1+ solid tumor cancers; and a recombinant fusion protein conjugate dubbed GTB-3550, which is undergoing a phase 1 clinical trial evaluating its effectiveness in treating refractory/relapsed acute myeloid leukemia, myelodysplastic syndromes, advanced systemic mastocytosis and other hematopoietic malignancies. It also develops a scFv candidate dubbed GTB-5550 for the treatment of B7H3+ solid tumor cancers.

The firm is focused on rapidly advancing its extensive TriKE platform of molecules which target various tumor types and positioning itself for future growth, which will bring in more investments into the firm.

GT Biopharma Inc. (GTBP), closed Tuesday's trading session at $3.15, up 10.5263%, on 54,062 volume. The average volume for the last 3 months is 121,209 and the stock's 52-week low/high is $2.61/$14.37.

NioCorp Developments (NB)

InvestorIntel, QualityStocks, Stock News Now and Pro-Edge reported earlier on NioCorp Developments (NB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NioCorp Developments Ltd. (NASDAQ: NB) (TSE: NB) (FRA: BR3) is a mineral development firm focused on exploring for and developing mineral deposits in North America.

The firm has its headquarters in Centennial, Colorado and was incorporated in 1987, on February 27th. Prior to its name change in March 2013, the firm was known as Quantum Rare Earth Developments Corporation. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers in Canada and the United States.

The company focuses on a superalloy materials project in Southeast Nebraska for the production of niobium, scandium, and titanium. It operates in one segment, which comprises of the exploration and development of mineral deposits in North America, in particular, the Elk Creek property, which is located in Johnson County, Southeastern Nebraska.

The enterprise’s Elk Creek Property is a carbonatite deposit located in the United States, which contains elements including niobium, titanium, and scandium, as well as rare earth products. This property is situated roughly 45 miles southeast of Lincoln, Nebraska, the state capital of Nebraska. The enterprise also owns one 226.43-acre parcel of land and associated mineral rights, and an additional 40 acres of mineral rights, within the carbonatite footprint.

The company, which recently entered into definitive agreements with two separate financiers, remains focused on advancing its efforts to launch construction of the Elk Creek project and proceed to commercial operation. The success of its endeavors will help generate additional revenues as well as value for its shareholders.

NioCorp Developments (NB), closed Tuesday's trading session at $2.17, up 10.1523%, on 144,632 volume. The average volume for the last 3 months is 189,501 and the stock's 52-week low/high is $1.93/$5.40.

NanoViricides Inc. (NNVC), QualityStocks, Wall Street Resources, StockMarketWatch, Stock Preacher, Beacon Equity Research, InvestorSoup, PennyStocks24, MarketClub Analysis, BUYINS.NET, StockProfessors, Jason Bond, TradersPro, SuperStockTips, Penny Stocks Finder, StockHideout, Penny Stock Craze, MissionIR, Stock Roach, SmarTrend Newsletters, MarketBeat, PennyStockShark, LightningStockPicks, CoolPennyStocks, StocksEarning, Stock Analyzer, Standout Stocks, USA Market News, FeedBlitz, Penny Stock Finder, Market Wrap Daily, OTCPicks, StreetAuthority Daily, Tiny Gems, HotOTC, TopStockAnalysts, Broad Street, Small Caps, PennyOmega, ProTrader, InvestorsUnderground, The Street, Jeff Bishop, InvestorPlace, The Online Investor, HotStockChat, Greenbackers, CRWEWallStreet, CRWEPicks, CRWEFinance, BullRally, BestOtc, AllPennyStocks, All about trends, DrStockPick, StockEgg, Stock Beast, Stock Rich, SmallCapVoice, Round Up the Bulls, RedChip, Real Pennies, Stock Source, ProfitableTrading, PennyTrader Publisher, MegaPennyStocks, Zacks, StreetInsider, Agora Financial, StockHotTips, Penny Pick Finders, Penny Invest, OTCReporter, Stockwire, MicrocapVoice, Stock Market Watch, MicroCapDaily, MarketClub and PennyToBuck reported earlier on NanoViricides Inc. (NNVC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

NanoViricides Inc. (NYSE American: NNVC) (FRA: NV3P) is a nano-biopharmaceutical firm that is engaged in the discovery, development and commercialization of therapies for treating viral infections and helping advance the care of patients with these life-threatening ailments.

The firm has its headquarters in Shelton, Connecticut and was incorporated in 2005, on April 1st by Anil R. Diwan. It operates in the health care sector, under the biotech and pharma sub-industry.

The company centers its clinical programs and research on certain anti-viral therapies and is working on adding to them its current portfolio of products via an in-licensing strategy and its clinical development and internal discovery programs. It is currently engaged in the application of Nano medicine technologies to the intricate issues of viral illnesses.

The enterprise’s product pipeline is made up of an anti-HIV nanoviricide dubbed HIVCide; DengueCide developed for treating all Dengue viruses; Nanoviricide eye drops for viral ailments that affect the external eye; and an injectable and an anti-influenza oral broad-spectrum nanoviricide known as FluCide, developed for both outpatients and hospitalized patients. The enterprise also develops a treatment for viral acute necrosis dubbed HerpeCide IntraOcular Injection and a formulation indicated for the treatment of ocular herpes keratitis, genital herpes, recurrent herpes labialis, herpes, chickenpox, PHN and shingles, dubbed HerpeCide Dermal Topical and Eye Drops. In addition to this, it is also engaged in HerpeCide program expansion drug projects for various herpes viruses; and researching and developing other nanoviricides for treating different indications and viruses.

The firm recently entered into an agreement with TheraCour Pharma Inc. to target encephalitis, conjunctivitis, dengue and Ebola. The development of cures for these ailments, which presently have no cures, will not only significantly boost the growth of both companies but also improve share prices and encourage more investments into the companies.

NanoViricides Inc. (NNVC), closed Tuesday's trading session at $3.31, up 9.2409%, on 648,341 volume. The average volume for the last 3 months is 91,158 and the stock's 52-week low/high is $1.00/$3.59.

Massimo Group (MAMO)

We reported earlier on Massimo Group (MAMO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Massimo Group (NASDAQ: MAMO) is a holding firm focused on the manufacture and sale of powersports vehicles and recreational watercraft.

The firm has its headquarters in Garland, Texas and was incorporated in 2022, on October 10th by David Shan and Rod N. Santomassino. It operates as part of the recreational vehicles industry, under the consumer cyclical sector. The firm primarily serves consumers in the United States.

The company manufactures, imports and distributes a diversified portfolio of products divided into a pair of main lines; a motorboat line consisting of pontoon and tritoon boats (Pontoon Boats) and a motor sports brand comprising of utility terrain vehicles, all-terrain vehicles, motorcycles, scooters, golf carts and a juvenile line from go-karts to balance bikes. It is also focused on developing new product lines, such as electric coolers, electric vehicle chargers, portable solar panels, power stations and electric Pontoon Boats. In addition to distributing its products, it intends to provide unparalleled customer service through a network, including over 600 motor vehicles and 5,500 marine third-party service providers across the United States, 24-hour customer support and an over 40,000 square foot parts facility. The company’s products are sold directly by it, in the e-commerce marketplace, and through a network of dealerships, distributors and chain stores.

The enterprise recently launched a Pontoon Boat Pilot Program in partnership with Tractor Supply Company, the largest rural lifestyle retailer in the U.S. This move allows the firm to offer Massimo Marine products to customers of Tractor Supply Company and may, in turn, help extend its consumer reach while opening it up to new growth and investment opportunities.

Massimo Group (MAMO), closed Tuesday's trading session at $3.51, up 0.0855432%, on 7,786 volume. The average volume for the last 3 months is 5.284M and the stock's 52-week low/high is $2.90/$4.66.

Match Group Inc. (MTCH)

InvestorPlace, Schaeffer's, Marketbeat, MarketClub Analysis, StocksEarning, The Street, Kiplinger Today, Daily Trade Alert, StreetInsider, Trades Of The Day, Daily Wealth, StockEarnings, Trading Tips, Zacks, Stockpalooza, Money Wealth Matters, Investopedia, Stock Stars, The Online Investor, Market Intelligence Center Alert, Wealth Insider Alert, Trading Concepts, QualityStocks, Stock Rich, StockHotTips,, Top Pros' Top Picks, Penny Invest, HotOTC, OTC Advisors, OTCReporter, Louis Navellier, CoolPennyStocks, CNBC Breaking News, StockEgg, StockMarketWatch, StreetAuthority Daily, SmallCapVoice, Barchart, BUYINS.NET, TopStockAnalysts, Standout Stocks, The Stock Dork, Investment U, InvestmentHouse, GorillaTrades, Wealth Daily, Epic Stock Picks, Energy and Capital, StockPickss, Monster Stox, PennyOmega, Cabot Wealth, InsiderTrades, Titan Stocks, Topgun stockpicks, Daily Profit, Early Bird, BloomMoney, FreeRealTime, DividendStocks, GusherStocks, wyatt research newsletter, XplosiveStocks,, The Motley Fool, Stock Traders Chat, The Trading Report, Stock Marketing Inc., Stock Market Watch, SpeculatingStocks, Wall Street Daily, TipRanks, Investiv, OTCPicks, Uncommon Wisdom, Profit Confidential, InvestorsObserver Team, Wise Alerts, WStreet Market Commentary, Investment House and Smart Investing Today reported earlier on Match Group Inc. (MTCH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Match Group (NASDAQ: MTCH), a leading provider of dating products available globally, has experienced a notable 5.4% increase in its share price since its last earnings report a month ago, outpacing the S&P 500. This growth is attributed to the company’s impressive first-quarter earnings for 2024, which saw a 4.8% increase in earnings per share from the previous year to 44 cents, and a 9% rise in revenues year-over-year to $859.65 million. The success of its popular dating apps, Tinder and Hinge, played a significant role in this performance, particularly in the Americas and Europe.

Despite the overall positive revenue growth, Match Group faced challenges with a 6% year-over-year decrease in the total number of payers to 14.93 million, slightly missing the Zacks Consensus Estimate. However, the company managed to significantly increase its total revenues per payer (“RPP”) by 16% year-over-year to $18.87. This was partly due to Tinder’s direct revenues growing by 9% year-over-year to $481.5 million, despite a 9% decline in the number of Tinder payers, which was attributed to pricing optimizations affecting conversion rates. Conversely, Hinge showcased exceptional growth, with a 50% surge in revenues to $123.75 million and a 31% increase in payers year-over-year.

The company’s operating costs and expenses rose by 15% year-over-year, resulting in a slight contraction in the adjusted operating margin to 33%. Despite this, Match Group ended the quarter with a strong cash position of $921 million and continued to return value to shareholders by repurchasing 5.6 million shares of common stock for $197.6 million. Looking forward, Match Group anticipates second-quarter 2024 revenues to be between $850 million and $860 million, indicating a modest year-over-year growth of 2% to 4%. The company expects Tinder’s direct revenues to show minimal growth, while projecting a significant 38% to 44% year-over-year increase in Hinge’s direct revenues.

However, the company’s stock recently saw a decrease of 1.28% to $31.61, with fluctuations between $31.34 and $32.02 during the trading session. Over the past year, MTCH’s shares have experienced highs and lows, trading as high as $49.24 and as low as $27.655, reflecting the volatile nature of the market. With a current market capitalization of approximately $8.4 billion and a trading volume of 967,980 shares, Match Group remains a significant player in the online dating industry. Despite the positive performance, the downward trend in investor and analyst sentiment, as indicated by a Zacks Rank #3 (Hold), suggests caution about the stock’s future performance, highlighting the competitive and ever-changing nature of the online dating market.

To view the full press release, visit

About Match Group

Match Group, through its portfolio companies, is a leading provider of digital technologies designed to help people make meaningful connections. Its global portfolio of brands includes Tinder(R), Hinge(R), Match(R), Meetic(R), OkCupid(R), Pairs(TM), PlentyOfFish(R), Azar(R), BLK(R), and more, each built to increase its users’ likelihood of connecting with others. Through the company’s trusted brands, it provides tailored services to meet the varying preferences of its users. Match Group’s services are available in over 40 languages to users all over the world.

Match Group Inc. (MTCH), closed Tuesday's trading session at $31.71, off by 0.4395604%, on 3,085,005 volume. The average volume for the last 3 months is 17.411M and the stock's 52-week low/high is $27.655/$49.24.

Canopy Growth Corp. (CGC)

InvestorPlace, Schaeffer's, The Street, MarketClub Analysis, Trades Of The Day, StocksEarning, StockEarnings, MarketBeat, Daily Trade Alert, Kiplinger Today, QualityStocks, The Online Investor, Wealth Insider Alert, Streetwise Reports, StreetInsider, CFN Media Group, Market Intelligence Center Alert, Investopedia, Zacks, Stock Up Featured, StreetAuthority Daily, The Wealth Report, Daily Profit, Top Pros' Top Picks, SmallCapVoice, Wall Street Grand, SeriousTraders,, StockMarketWatch, INO Market Report, Money Morning, Early Bird, Profit Trends, Louis Navellier, Trading For Keeps, Investors Underground, Jim Cramer, Inside Trading, CNBC Breaking News, StocksToBuyNow, Cannabis Financial Network News, MarketClub, BUYINS.NET, Outsider Club, Tim Bohen, Cabot Wealth, Beat The Street, VectorVest, AllPennyStocks, Trading Concepts, TradersPro, Wealth Daily, Insider Wealth Advice, Investment U, Profit Confidential, Timothy Sykes, Investors Alley, TheTradingReport, Technology Profits Daily, Stock Gumshoe, Rick Saddler, Money and Markets, Raging Bull All Access, 24/7 Trader and InvestmentHouse reported earlier on Canopy Growth Corp. (CGC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

As the United States moves closer to rescheduling and legalizing cannabis, critical questions emerge about who should benefit from these changes and who is best suited to craft equitable cannabis policies. Big businesses frequently have a big say in what laws are passed, and the cannabis industry seems to be no exception. But who, in the opinion of Americans, ought to have more influence over cannabis laws?

A recent survey by the Parabola Center, a nonpartisan think tank made up of experts in drug policy and law who advocate for marijuana legalization with a special emphasis on small enterprises and individuals, provides insight into public opinion. When respondents were asked who they trusted to develop effective marijuana policies, they provided the following responses:

  • 67%: individuals with firsthand experience
  • 56%: cannabis users
  • 55%: social-equity advocates
  • 24%: representatives from pharmaceutical companies
  • 22%: federal government
  • 18%: executives from the tobacco industry
  • 13%: executives from the alcohol industry

It makes sense that people have little faith in executives in the alcohol and tobacco industries, given the harmful effects of their products. Furthermore, as their regular customer base shrinks, a few of these businesses are keen to join the cannabis space.

When asked about their top concerns regarding marijuana policy, respondents said the following:

  • 68%: promoting social equity
  • 68%: ending cannabis-related arrests
  • 65%: ensuring access to marijuana
  • 49%: fostering a sharing society
  • 42%: preserving cannabis culture
  • 27%: keeping cannabis illegal

The war on drugs, including marijuana prohibition, disproportionately harmed certain communities. Many believe that fair policies could help address some of the injustices caused by past enforcement. In fact, according to 61% of respondents, legalization should help individuals who have been negatively impacted by current prohibitions.

President Joseph Biden has also acknowledged the negative impacts caused by outdated cannabis policies. He stated in 2022 while announcing a review of how marijuana is classified, that many lives have been upended because of failed cannabis policy approaches, and it was time to make the mistakes right.

When asked who should benefit from cannabis legalization, respondents identified the following top three groups:

  • 85%: people using marijuana for medicinal purposes
  • 73%: workers in the marijuana industry
  • 63%: recreational users

Conversely, the least-favored groups included alcohol companies, the tobacco industry, large corporations and pharmaceutical companies.

The survey, conducted in September 2023, involved 404 U.S. adults. Although not extensive, it may be one of the first surveys to explore this particular angle of marijuana policy and legalization.

Entities such as Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) will be pleased to see that the general public sentiment is in favor of ending cannabis prohibition at the federal level and allowing experienced industry professionals to be in charge of policy making and implementation.

Canopy Growth Corp. (CGC), closed Tuesday's trading session at $7.32, up 0.5494506%, on 3,115,464 volume. The average volume for the last 3 months is 81,498 and the stock's 52-week low/high is $2.755/$19.20.

Seelos Therapeutics Inc. (SEEL)

QualityStocks, MarketBeat, StockEarnings, StockMarketWatch, MarketClub Analysis, TradersPro, PsychedelicNewsWire, Schaeffer's, Prism MarketView, BUYINS.NET, Trades Of The Day, The Online Investor and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A number of companies involved in the psychedelic space saw their stocks plummet during premarket trading earlier this week after an advisory panel counseled the U.S. Food and Drug Administration (FDA) against approving the use of MDMA as a treatment for post traumatic stress disorder (PTSD).

MDMA, commonly known as molly or ecstasy, is a stimulant and psychedelic drug that comes in powder or pill forms. Currently, the drug is classified under Schedule I of the Controlled Substances Act, together with drugs such as LSD, marijuana, heroin and peyote. Drugs under this classification are said to have no accepted medical use and a high abuse potential. However, numerous studies and trials conducted in the last couple of years have determined that the drug may be useful in treating PTSD.

It appears this wasn’t enough to convince the 11-member advisory panel, as nine of them voted against the drug’s use in managing the condition. Their decision was based on concerns that available evidence doesn’t demonstrate that the drug’s benefits outweigh its risks or that it was effective. The panel members also cited flawed research conduct and trials as part of their reasoning, noting that there wasn’t enough follow-up data on patient outcomes as well as diversity in trial participants.

While the panel’s advice doesn’t dictate the agency’s final decision on the matter, it is known that the agency has a lot of confidence in the advice it gets from its experts.

This announcement marks a huge setback for clinicians and companies in the United States who were hoping to exploit the therapeutic potential of psychedelics such as MDMA. Companies such as Mind Medicine, based in New York; Cybin, a Canadian company; atai Life Sciences, based in Berlin; and Compass Pathways, a British biotech company, have seen their stocks drop between 10–15% this week.

Lykos Therapeutics, the drug’s sponsor, has observed investor confidence reduce following the announcement. One of the trials demonstrated that MDMA therapy reduced many PTSD symptoms with minimal serious side effects.

Other companies that have been affected include GH Research, a clinical-stage pharmaceutical company focused on developing new treatments of neurological and psychiatric disorders, which saw a 3.5% drop in its stocks. Relmada Therapeutics, a biotechnology company that targets conditions of the central nervous system, also saw its shares fall by about 5%.

Surprisingly, some companies had their shares go up during this same period. Seelos Therapeutics Inc. (NASDAQ: SEEL), a biopharmaceutical company evaluating the use of psychedelics in treating neurological illnesses, saw its shares rise by almost 2%.

The FDA is slated to make a final decision on the matter in August 2024.

Seelos Therapeutics Inc. (SEEL), closed Tuesday's trading session at $1.02, off by 1.9231%, on 99,359 volume. The average volume for the last 3 months is 2.305M and the stock's 52-week low/high is $0.98/$398.40.

Momo Inc. (MOMO)

StocksEarning, MarketClub Analysis, QualityStocks, InvestorPlace, StockEarnings, Schaeffer's, Marketbeat, Market Intelligence Center Alert, Zacks, The Street, Trades Of The Day, Kiplinger Today, Daily Trade Alert, StreetInsider, The Street Report,, BUYINS.NET, The Online Investor, FreeRealTime, Market Report, ChineseWire, Trading Concepts, Louis Navellier, TradersPro, Wealth Insider Alert, StreetAuthority Daily, TopStockAnalysts, Money Morning, Investopedia, DividendStocks, Daily Wealth, PennyDoctor, TipRanks, Greenbackers, StockMarketWatch, StocksImpossible, Street Insider, OTCBB Journal, Early Bird, First Penny Picks, ChartAdvisor, Barchart, CrashTrade, Investing Signal, InvestmentHouse, Jason Bond, AskSlapper, Orbit Stocks, Profit Confidential, Promotion Stock Secrets, Short Term Wealth, Terry's Tips, The Best Newsletters, The Stock Dork and One Hot Stock reported earlier on Momo Inc. (MOMO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Former U.S. President Donald Trump has joined Chinese social media app TikTok despite calling the video-sharing application a security threat during his presidential tenure. In a major reversal of his position on TikTok, Trump said he was honored to join the popular social media app he previously tried to ban in the United States.

The embattled former head of state quickly gained a whopping five million followers and surpassed the Biden administration’s following of only 355,000. With the popular video-sharing app primarily filled with younger users from Gen Z, Trump is likely trying to attract young American voters to his camp amid the historic trial he has been going through in New York.

Trump made his first TikTok post just two days after he became the first former head of state and presidential nominee in the history of the nation to become a convicted felon. In his first post to the platform, Trump posed with UFC chairman Dana White at a UFC fight in Newark and said that “it’s an honor,” while he waved and took selfies with fans at the event. A day after the post, Trump’s TikTok account had more than 1.1 million followers, more than a million likes and a massive 24 million views.

According to the former president’s spokesman Steven Cheung, Trump’s move to the controversial video-sharing application is part of his efforts to reach a younger audience that is interested in anti-Biden and pro-Trump content. With most young voters in the U.S. being left leaning, Trump may struggle to convert his TikTok following into actual votes. He is currently fielding plenty of negative press, and may polls indicate that he is trailing behind President Biden after his recent felony conviction.

President Biden has also taken steps to boot TikTok from the U.S. market. Trump tried to ban the app via an executive order that was eventually squashed by the courts following a suit by TikTok. Biden, on the other hand, signed a measure that could ban the application from operating in the U.S. in April even though his campaign joined the platform in February.

The bill requires that Tik Tok parent company ByteDance sell the social media platform in nine months with an extra three months thrown in if the platform’s sale is in progress. If ByteDance doesn’t make the sale within the allotted timeline, the U.S. will ban TikTok within its borders.

Trump’s entry onto TikTok shows just how influential the video-sharing platforms by entities such as ByteDance, Momo Inc. (NASDAQ: MOMO) and others are in giving different people a platform to reach a wide audience at minimal cost.

Momo Inc. (MOMO), closed Tuesday's trading session at $5.58, off by 1.0638%, on 1,346,308 volume. The average volume for the last 3 months is 831,873 and the stock's 52-week low/high is $4.79/$11.12.

The QualityStocks Company Corner


The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

This year's Proof of Talk Paris summit promises to be a key event that will bring together VCs, founders and developers. Held at the iconic French palace, the event will provide a platform for tech experts and enthusiasts to help others understand the importance of how traditional economic forums converge with the dynamic innovation of Web3. Organized by X-Ventures, Proof of Talk will allow those attending to have thought-provoking discussions and share insights about blockchain technology. Some of the keynote speakers of the event include ConsenSys CEO and founder Joseph Lubin; Franklin Templeton's CEO Jenny Johnson; Draper Associates founder Tim Draper; Animoca Brands founder Yat Siu; Algorand Foundation's CEO Staci Warden; Mihailo Bjelic Polygon's cofounder; Aave founder Stani Kulekhov; DFINITY Foundation's chief scientist and founder Dominic Williams; MultiverS CEO and founder Beniamin Mincu; Solana Foundation president Lily Liu; Tron founder Justin Sun; and Aptos Labs founder Mo Shaikh, among many other carefully selected speakers. These speakers are expected to address crucial issues influencing global policy and driving innovation. The summit will be moderated by MacKenzie Sigalos from CNBC. Events such as these often result in collaborations that yield innovations which enterprises such as NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW) integrate into their operations in order to offer superior services and products to their customers.

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Tuesday's trading session at $1.14, up 0.8849558%, on 10,856 volume. The average volume for the last 3 months is 3,912 and the stock's 52-week low/high is $1.06/$3.08.

Recent News

Correlate Energy Corp. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Energy Corp. (OTCQB: CIPI).

Correlate Energy (OTCQB: CIPI) is working to develop the first microgrid utility in the country. According to the announcement, the company is partnering with Compass Energy Platform and Distributed Energy Capital ("DEC") on the landmark initiative, which will be a major advancement in adopting renewable utility infrastructure, ensuring reliable and resilient clean energy. The project is being led by Cuyahoga Green Energy ("CGE") and will be the first new county utility for Cuyahoga County in more than 75 years. To begin with, the project calls for the development of four microgrids, totaling approximately $400 million, with opportunities for follow-on initiatives. Each microgrid will serve as small-scale electricity system that can operate independently from the main grid, thereby providing an uninterrupted supply of clean and reliable energy to its interconnected customers. Correlate Energy will operate DEC, which will provide financial and technical development services designed to support the partnership by structuring near and long-term project financing while Compass Energy Platform will serve as the operational and strategic partner responsible for managing the utility's operations. "I am thrilled to see the culmination of our team's historical experience in executing a project of this magnitude at the district level," said Correlate Energy president and CEO Todd Michaels in the press release. "This initiative addresses a significant problem by providing resilient energy solutions for this county and opens up tremendous opportunities for our company to meet similar needs across North America."

To view the full press release, visit

Correlate Energy Corp. (OTCQB: CIPI) is a publicly-traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation.

The energy grid in the U.S. is insufficient for the booming clean energy trend, and current infrastructure is limiting green energy distribution. Constructing the needed infrastructure to address this demand imbalance will cost billions and be far too slow, positioning decentralized systems, like those on offer from Correlate, in a key position for heightened demand.

Correlate has identified several key economic drivers powering the decentralized energy trend, including:

  1. Real Cost Savings – Customer pays zero money down and gets an instant electrical price discount to current rates.
  2. Massive Project Investment Funding – The International Energy Agency estimates that over one billion dollars per day will be invested in solar energy in 2023.
  3. Consistent Long-Term Incentives – The Inflation Reduction Act is a game-changer, supercharging renewables with $1.2 trillion in tax credits for 10 years of market support.
  4. Robust Customer Demand – Wood Mackenzie expects the U.S. solar industry to nearly triple in size over the next five years.

Correlate’s team of multi-decade experts who have worked with renowned global brands are positioning the company to make the most of this opportunity while consolidating a fragmented industry. Collectively, the team has developed, financed and deployed over $2 billion in clean energy projects to date.

Three-Pronged Strategy

Correlate is leveraging a three-pronged strategy aimed at driving shareholder value:

  1. Sell – Correlate seeks to finance, develop and profitably sell localized clean energy solutions and microgrids to industrial, commercial and residential customers.
  2. Retain – Correlate plans to retain ownership of some of these energy systems and thereby realize ongoing, reliable cash flow.
  3. Acquire – Correlate seeks to acquire proven renewable energy companies in order to exponentially grow earnings per share for investors.

This strategy is enhanced by current investment trends. Clean energy earnings are being sought after by investors. In Q4 2022, the median EBITDA multiple for green energy companies was 12.3x, according to Finerva.

Market Outlook

Over the next decade and beyond, renewable energy growth is expected to come primarily via decentralized systems like those offered by Correlate.
The Inflation Reduction Act enacted in late August 2022 is likewise expected to drive growth for the company by providing new tax incentives that reduce costs for clients and/or elevate returns to investors.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings, yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which are very different from traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue, known as the ‘split incentive’, unlocking the majority of the addressable market.

A key portion of Correlate’s strategy relates to consolidation of what has been a fragmented industry. By uncovering opportunities to improve efficiencies through strategic M&A activities, the company intends to enhance profitability throughout its operations.

Management Team

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

Dave Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jed Freedlander is the company’s Chief Development Officer. He has a background in infrastructure development and investment and a strong legal, commercial and finance acumen. Mr. Freedlander has a proven track record in leading complex public-private partnership (P3) and energy transactions and is instrumental in driving Correlate’s strategic development initiatives.

Roger Baum is Executive VP Operations at Correlate. With over 20 years of experience at Core Construction, he brings to the company a wealth of knowledge and a strong track record in delivering successful commercial construction projects.

Jason Loyet is Director of Solar Energy for Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Correlate Energy Corp. (OTCQB: CIPI), closed Tuesday's trading session at $0.689, up 36.4627%, on 630 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.08/$.

Recent News

GivBux Inc. (OTC: GBUX)

The QualityStocks Daily Newsletter would like to spotlightFathom GivBux Inc. (OTC: GBUX) .

GivBux (OTC: GBUX), a publicly traded super app and charitable giving platform, today announced significant progress toward its goal of becoming a fully reporting OTCQB Corporation. "We are happy to report that we have been working diligently on our ‘Promises Made, Promised Kept' commitment to transparency and accountability to our stakeholders," said GivBux President Umesh Tim Singh. "We anticipate that our independent auditors will complete their task within the next few weeks, and that we will be filing our SEC Form 10 and all its required documentation shortly thereafter. I am also pleased to report that while these steps are being taken, work on all our other projects and activities has continued unabated. We will be releasing additional news and updates about these as well in the coming weeks and months."

To view the full press release, visit

GivBux Inc. (OTC: GBUX) is a publicly traded super app and charitable giving platform. The company is creating a sharing economic community of brands and consumers in which consumers have an easier and more convenient way to shop and buy, merchants have a more efficient and profitable way to advertise, and charities receive built-in contributions from the community’s transactions.

The GivBux Super App revolutionizes shopping by offering a user-friendly tool to make purchases swiftly at over 100 national retailers, along with an expanding roster of local merchants. Users earn cash back on every purchase, a portion of which can be directed toward a charity of their choice, embodying GivBux’s commitment to giving back. Additionally, the app is evolving to include numerous functionalities like social networking, e-commerce, banking, messaging, food delivery and transportation, following the super app model.

GivBux is forging a new path in charitable giving, with aspirations to build the largest community of givers in the United States, and eventually globally. The company believes it is uniquely positioned to make a major contribution to society by overlapping the worlds of commerce and philanthropy.

The GivBux Super App is currently available for free on the Google Play Store and the Apple App Store.

The company is headquartered in Newport Beach, California.


The company, through wholly owned subsidiary GivBux Global Partners Inc., is engaged in the fintech mobile wallet sector, specifically as a point-of-sale payment system by means of a consumer mobile wallet. GivBux uses smartphone technology to bridge consumers and merchants together without the need for traditional plastic cards or paper cash.

The GivBux mobile app has been designed to store, send and receive funds; donate; and make real-time purchases at top retail brands, restaurants and other venues. The brands benefit, because they are empowered with a data-rich marketing tool to reach and retain consumers through their mobile phones.

With GivBux, recipients can use funds instantly by paying with their mobile phones at thousands of locations. GivBux rewards all users for using the app every time they make a purchase and every time their friends, friends of friends and stranger friends make purchases with the GivBux mobile wallet. These rewards can be redeemed for cash to pay at participating retail stores, restaurants, cinemas, entertainment venues and more.

Moreover, GivBux allows users to contribute to a charity or worthy cause of their choice. To encourage giving and recommendations, a trending ‘Top 10 List’ of all charities will be generated and displayed on the mobile wallet based on ongoing contributions by GivBux users.

Market Opportunity

A report from Future Market Insights, a New York-based market research organization, estimated the worldwide mobile wallet market at $9.5 billion in 2023. The report projects that in 2024 the industry is likely to reach a valuation of $11.9 billion, and, by 2034, the mobile wallet market is forecast to grow to a value of $138.5 billion, achieving a CAGR of 27.8% over the forecast period.

Key market growth drivers include payment convenience, transaction security and continuing technological innovation. The report points out that mobile wallet payments are widely accepted worldwide, fueled by a rise in digital transactions and a growing use of mobile phones for simple and effective payment options. Innovations like blockchain integration, contactless payments and artificial intelligence are improving functionality and user experience while staying ahead of rapidly evolving digital payment trends, according to the report.

Management Team

Umesh Singh is President and Director at GivBux. He is a Certified Professional Accountant (Canada) with more than 25 years of experience in accounting and finance. He began his career at PwC before joining Hayes Stuart Little & Company (now Grant Thornton), where he was Senior Accountant-Manager and later Partner. Prior to being named GivBux president, he was a member of the GivBux Advisory Board for more than three years.

Michael Arnkvarn is Vice President of International Business Development at GivBux. He has over 30 years of experience in management, sales and marketing. He managed several medium and large agribusiness and environmental businesses before founding Collagenna Skin Care Products, a natural health products and cosmetics company, in 2004. He has been CEO of multiple public small-cap companies and co-founder of a start-up cannabis company that eventually sold for more than $800 million.

GivBux Inc. (OTC: GBUX), closed Tuesday's trading session at $0.7, up 3.0928%, on 38,535 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.205/$2.011.

Recent News

Bebuzee Inc. (OTC: BBUZ)

The QualityStocks Daily Newsletter would like to spotlightFathom Bebuzee Inc. (OTC: BBUZ) .

Bebuzee (OTC: BBUZ), a leading social media and digital entertainment platform, has unveiled two groundbreaking live-streaming features in its revolutionary super app: TikTok-Style Live Streaming and YouTube Style Live Streaming. According to the announcement, these additions to the app are designed to enhance user engagement and transform the digital experience for Bebuzee users, allowing them to experiment with content and connect with creators and communities in new ways. The TikTok-style live streaming feature offers the ability to broadcast short, engaging live videos in real time, an ideal way to create spontaneous content, live interactions and viral moments. The YouTube-style live streaming feature also supports live content but is designed to support longer, more in-depth broadcasts, such as shows, tutorials, webinars and other extended content. "We are incredibly excited to launch these new live streaming features," said Bebuzee CEO Joe Onyero in the press release. "By incorporating TikTok- and YouTube-style live streaming into our super app, we are providing our users with powerful tools to connect, create and engage like never before. This is a significant milestone in our journey to transform the digital entertainment landscape and offer a truly unique and immersive experience for our community."

To view the full press release, visit

Bebuzee Inc. (OTC: BBUZ), formerly Engage Mobility Inc., is a social platform and streaming service focused on development and deployment of America’s first superapp. The superapp will allow members to watch a wide variety of content, such as movies, series, documentaries and talk shows, on any internet-connected device.

Bebuzee’s technology scans the world’s news, features and information-flow to give its dedicated readers the best of the internet in one place – a one-stop platform for breaking news, interesting and important blogs, videos and photos.

The core features of the superapp include video streaming; photo sharing; Bebuzee Messaging service, which allows users to send text and voice messages and make voice and video calls; Shortbuz, used to make a variety of short-form entertaining videos; Blogbuz, a resource for people without time to scavenge the internet and other sources for news and information; Properbuz global real estate search; global tradesmen search; location reviews of neighborhoods, cities and even regions to help others find their ideal rental or real estate purchase; ShoppingBuz, a unique technology-driven e-commerce platform which gives merchants incredible tools to sell their products; Bebuzee Pay, a mobile payment and digital wallet service that allows users to make mobile payments and online transactions; TravelBuz, an online travel booking service; EventBuz, a ticket exchange and resale platform; and FlightBuz, a flight search engine.

The company is headquartered in Miami.

Introducing the Superapp to Western Markets

A superapp is a mobile phone app that offers a wide range of services within a single platform. This technology allows users to access various services without downloading and switching between multiple apps.

While superapps are popular in many parts of the world, including Latin America, Africa, the Middle East, Asia and Russia, they have achieved little adoption in Western markets. Perhaps the most widely known superapp is WeChat, which is estimated to have as many as 1.24 billion users, mostly in China.

Bebuzee aims to be the first developer to introduce and grow to widespread popularity a superapp in the U.S. and Europe. It took a strong step toward achieving this goal during the COVID-19 pandemic, when Bebuzee’s user base surged by 78% with over 42 million new users.

Whereas most social platforms are generic and only local postings make them somewhat relevant to local communities, Bebuzee has localized its platform for most countries by providing local content, entertainment and information that is frequently updated and refreshed.

The company says the average age of its superapp users is 39, with female users making up 62.8% of its user base. Its monetization strategy includes sales of video advertising, sponsored posts, banner ads and premium listings, as well as promotion of featured brands and property listings.

Market Opportunity

A report from Allied Market Research, a global market research, consulting and advisory firm, estimated that the worldwide superapps market was valued at $58.6 billion in 2022. The report projects the market to expand to $722.4 billion by 2032, growing at a CAGR of 28.9% for the forecast period.

The report identifies a few of the most popular superapps as Rappi in Latin America, Snapp in Iran, Line in Japan and Yandex Go in Russia and Kazakhstan.

Increasing adoption of mobile services and growing advancements in digital technologies are driving the growth of this market. In addition, a rise in government support for promoting the use of superapps is lending to expansion, according to the report.

Integration of blockchain technology in superapps is likewise anticipated to provide numerous opportunities for the expansion of the market during the forecast period, the report states.

Management Team

Joseph Onyero is Founder and CEO of Bebuzee. He has a background of managing multiple products from ideation to market launch and profitable monetization and has been building commercial web presences since 2005. He has worked as a Chief Marketing Officer and in business development. He previously owned and operated a travel and tourism company. He began in 2005 working on the concept and features that have evolved into the Bebuzee suite. He has grown Bebuzee from a living room start-up into a U.S. publicly traded company.

Claudia S. Spagnuolo is Chief Operating Officer at Bebuzee. She began with the company in 2014 as a user experience manager before being promoted to CMO in 2017. She previously worked as an assistant marketing director at the National Secretariat of the union CISL in Italy. Prior to that, she also worked as a researcher at the Complutense University of Madrid on issues of corporate management. She speaks three languages and holds a bachelor’s in political science and a master’s in administration from the University of Perugia in Italy.

Bebuzee Inc. (OTC: BBUZ), closed Tuesday's trading session at $0.069, up 30.1887%, on 22,900 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.01955/$0.359.

Recent News

Nightfood Holdings Inc. (OTCQB: NGTF)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (OTCQB: NGTF).

Nightfood Holdings (OTCQB: NGTF), a forward-thinking acquisition and development holding company, announced that it is partnering with IBN, a multifaceted financial news and publishing company for private and public entities. Nightfood has chosen IBN to assist with its corporate communications initiatives as the company focuses on expanding operations through value-added acquisitions in high-growth categories. Nightfood is committed to identifying and capitalizing on market trends within the hospitality, food services and consumer packaged goods spaces. Nightfood Inc., an NGTF subsidiary, offers snacks that are formulated by sleep and nutrition experts to satisfy nighttime cravings while also supporting better sleep. Nightfood also owns Future Hospitality Ventures Holdings, which operates under the brand roboOp365 and delivers cutting-edge artificial intelligence ("AI")-enabled automation and robotic solutions for hospitality providers. "As part of the client-partner relationship, IBN will leverage its investor-based distribution network of over 5,000 key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for Nightfood," stated the announcement.

To view the full press release, visit

Nightfood Holdings Inc. (OTCQB: NGTF) is a visionary holding company focused on identifying and capitalizing on explosive market trends within hospitality, food services and consumer packaged goods. By leading newly emerging categories and seizing opportunities in markets undergoing transformational upheaval, the company’s mission is to create unparalleled upside potential in industries ripe for innovation and growth.


Nightfood Inc.

The company’s flagship subsidiary, Nightfood Inc., is changing the way the world snacks at night. Humans are biologically hard-wired to crave sweets and fats at night – a survival mechanism from our hunter-gatherer days. Modern consumers know bingeing excess calories before the long nightly fast is no longer necessary for survival, but exploding screen time and decreased willpower at night results in over 90% of American adults snacking between dinner and bed every week, contributing to an estimated one billion nighttime snack occasions weekly (according to

The most popular choices – ice cream, cookies, chips and candy – are not only unhealthy but also impair sleep quality due to their nutritional profiles. Nightfood snacks are uniquely formulated by sleep and nutrition experts to satisfy nighttime cravings AND support better sleep.

Market Opportunity

Euromonitor International projects the American snack market will grow from $150 billion in 2022 to $170 billion in 2027. Snacking between dinner and bed is estimated to account for over $60 billion annually, creating an opportunity for a multi-billion-dollar sub-category to emerge in the coming years: sleep-friendly snacking.

Nightfood is the brand pioneering that category.

Nightfood’s innovation has led to partnership overtures from global giants, including the largest food and beverage company in the world, Nestlé, with whom Nightfood completed a “test-and-learn” joint initiative in 2023.

Management believes that successfully scaling Nightfood’s 2024 direct-to-consumer launch of sleep-friendly cookies will bring the category to life, opening the door for partnerships with and potential acquisition by global snack giants seeking to lead this potential billion-dollar emerging sub-category.

Future Hospitality Ventures Holdings Inc. (d/b/a roboOp365)

Future Hospitality Ventures Holdings, operating under the brand roboOp365, is revolutionizing the hospitality industry with cutting-edge automation and robotic solutions.

roboOp365 enhances operational efficiency and guest experiences through innovative technologies, including automated culinary bot, server robots and AI-enhanced applications. roboOp365 helps hospitality providers reduce costs, streamline operations and deliver superior service by integrating these advancements.

Market Opportunity

The robots-as-a-service (RaaS) business model has gained significant traction, super-charged by the COVID-19 pandemic, which instantly catalyzed game-changing growth and application. According to Verified Market Research, the service robotics market is projected to reach $173.17 billion by 2030, growing at a compound annual growth rate (CAGR) of 21.25%. Compared to Asia, the United States market is in the early stages of adopting these technologies, but acceptance is accelerating aggressively.

Several factors are driving this trend. Key industries such as hotels and restaurants are still struggling to rebound from the pandemic’s impact, hoping to return to pre-pandemic levels, if possible. Such recovery will largely be dependent upon service robots. In California specifically, factors such as rising labor costs, more rigorous labor laws and ongoing high turnover rates in labor-intensive sectors make it impossible for businesses to survive, thrive and compete without robotics.

Innovation Across Sectors

Nightfood Holdings Inc. is dedicated to driving innovation across its focus sectors of food services, automation and hospitality applications. In food services, the company leverages automation technology to drive operational efficiency for operators while meeting evolving consumer needs. In the hospitality industry, it’s deploying solutions that redefine guest experiences. Nightfood’s consumer-packaged goods initiatives are key to breakthrough trends in health and wellness.

Synergizing Food and Technology

The synergy of food and technology within Nightfood Holdings Inc. creates a holistic approach to innovation and automation. By integrating these areas, the company offers comprehensive solutions that address multiple facets of market needs. Its automation and artificial intelligence solutions in food service and hospitality create a seamless and enhanced consumer experience.

Through this integrated approach, Nightfood Holdings Inc. not only meets current market demands but also anticipates and influences future trends, positioning itself as a leader in innovation across these interconnected sectors. Synergies in these related and explosive categories result in operational efficiency and benefits for the company’s customers and partners and outsized upside and opportunity for its investors.

Management Team

Sean Folkson is the Chairman and President of Nightfood. He founded Nightfood when he couldn’t find a solution to his nighttime snacking problem. Recognizing the growing body of research linking nutritional intake with sleep quality, he launched the first snack brand specifically formulated to give consumers better, healthier and more sleep-friendly snacks for that peak-cravings slot between dinner and bed. He is a serial entrepreneur and problem-solver, having previously founded Specialty Equipment Direct, an online distributor of floor removal equipment, and, a pioneering company in online affiliate marketing.

Lei Sonny Wang is the CEO of Nightfood Holdings. He is a strategist and business driver for early-stage and growth-stage companies. He is the founder and former CEO of Future Hospitality Ventures Holdings Inc., which was acquired by Nightfood Holdings Inc. At Future Hospitality, he leveraged his significant international business development experience into distribution relationships with leading global robotics manufacturers. At Nightfood, he is working to grow revenue and improve performance and profitability across all subsidiaries.

Nightfood Holdings Inc. (OTCQB: NGTF), closed Tuesday's trading session at $0.01355, up 20.9821%, on 158,600 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0075/$0.0425.

Recent News

Annovis Bio Inc. (NYSE: ANVS)

The QualityStocks Daily Newsletter would like to spotlight Nightfood Holdings Inc. (NYSE: ANVS).

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug-platform company developing novel therapies for neurodegenerative disorders such as Alzheimer's disease ("AD") and Parkinson's disease ("PD"), is reporting the results of its recent phase 2/3 Alzheimer's study. The study was designed to evaluate Buntanetap, the company's lead drug candidate. According to the report, key findings indicate that Buntanetap showed statistically significant efficacy and safety in the treatment of both carriers and noncarriers of Apolipoprotein E4 (APOE4), a genetic cause of AD. The company has scheduled an investor call for today at 4:30 p.m. ET to provide more detailed information and outline future development plans for Buntanetap. Buntanetap targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein and TDP43. "Encouraged by these results, Annovis Bio is planning an 18-month phase 3 trial focusing on biomarker-positive early-AD patients," stated the company in the press release. "This trial aims to further validate Buntanetap's efficacy and safety profile and will be conducted under the guidance of the FDA."

To view the call, visit

To view the full press release, visit

Annovis Bio Inc. (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Annovis Bio stands out by developing a drug that targets multiple neurotoxic proteins simultaneously, aiming to restore axonal and synaptic activity. This innovative approach aims to treat memory loss and dementia associated with AD and body and brain dysfunction associated with PD, making Annovis a unique player in the neurodegeneration space.

Lead Drug Candidate: Buntanetap

Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43. This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying. Unlike monoclonal antibody therapies, Buntanetap is an orally available small molecule capable of inhibiting multiple neurotoxic proteins at once, positioning it as a comprehensive solution for neurodegenerative diseases.

In a recent Phase II/III Alzheimer’s study, Buntanetap demonstrated statistically significant efficacy. Patients with early AD showed a significantly higher rate of improvement in ADAS-Cog 11 scores across all treatment doses compared to placebo, with a -3.3 point improvement compared to -0.3 for placebo (p < 0.01). Plasma Tau protein levels also reduced, consistent with previous Phase II biomarker data, further validating Buntanetap’s mechanism of action.

Similarly, in the Phase III study of Buntanetap in patients with early Parkinson’s disease, significant advancements were observed. Topline data results are anticipated in June 2024. Preliminary findings indicate promising results in improving cognitive and motor function, underscoring Buntanetap’s potential as a transformative therapy for Parkinson’s disease.

Market Opportunity

The aging population presents a significant market opportunity, with nearly 7 million Americans currently suffering from Alzheimer’s Disease (AD), a figure projected to rise to almost 13 million by 2050 (Alzheimer’s Association) (Republican Policy Committee). Additionally, approximately 1.2 million people in the U.S. have Parkinson’s Disease (SingleCare).

The economic burden of Alzheimer’s is immense, with care costs expected to reach $360 billion in 2024 and escalate to nearly $1 trillion annually by 2050. The need for effective, comprehensive treatments like Buntanetap is more critical than ever.

Company Highlights

  • Innovative Therapeutic Approach: Annovis Bio uniquely targets multiple neurotoxic proteins, aiming to restore nerve cell health and improve cognitive and motor function in AD and PD patients.
  • Robust Clinical Data: Phase II/III studies show significant improvements in cognitive function and biomarker levels in early AD patients.
  • Groundbreaking Clinical Insights: Preliminary results from Phase II studies indicate significant improvements in motor functions and speed in patients with Parkinson’s Disease (PD).
  • Upcoming Phase III Trials: Plans are underway for an 18-month Phase III trial focusing on biomarker-positive early AD patients, designed to further validate Buntanetap’s disease-modifying potential.
  • Capital Efficiency: Annovis Bio is capital-efficient, with zero debt and multiple global patents extending into the 2040s.

Management Team

Maria L. Maccecchini, Ph.D., Founder, President, CEO, and Executive Board Member, founded Annovis Bio in May 2008 with the mission to develop better therapeutics for Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. She has previously been a partner and director at two angel groups, Robin Hood Ventures and MidAtlantic Angel Group, and founded Symphony Pharmaceuticals/Annovis, which was sold to Transgenomic in 2001. Her extensive experience includes roles such as General Manager at Bachem Bioscience and Head of Molecular Biology at Mallinckrodt. Dr. Maccecchini holds a Ph.D. in biochemistry from the Biocenter of Basel, with postdoctoral work at Caltech and the Roche Institute of Immunology.

Cheng Fang, Ph.D., Senior VP of Research and Development, is an accomplished neuroscientist with two decades of experience in neurodegenerative diseases. She has a successful track record of scientific publications and contributions, coupled with extensive pre-clinical and clinical development experience. Dr. Fang has been instrumental in advancing the understanding of neurodegenerative disease mechanisms and developing therapeutic strategies.

Michael Christie, Ph.D., VP of Process Chemistry, has over 40 years of experience in the pharmaceutical industry, focusing on process chemistry R&D, pilot plant production, and GMP operations. He has held senior management positions at companies such as SmithKline, Rhodia, Teva, and Cephalon, and founded a contract process R&D service company, which was later acquired by ChiRex. Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.

Melissa Gaines, Senior VP of Clinical Operations, is an accomplished clinical research professional with over 20 years of experience across academia, contract research organizations, and pharmaceutical companies. She has proven abilities in monitoring and managing Phase I to IV clinical trials, specializing in CNS disorders and extending to a broad range of therapeutic indications. Her CNS experience spans from small Phase I and II studies to large global Phase III trials in Alzheimer’s disease, Parkinson’s disease, sleep disorders, and various psychiatric diseases in both adult and pediatric populations. In her current role, she oversees and supports all clinical project activities, driving operational success and ensuring high-quality clinical outcomes.

Learn more about the Annovis Bio team on LinkedIn.

Annovis Bio Inc. (NYSE: ANVS), closed Tuesday's trading session at $6.77, up 4.1538%, on 368,394 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $4.79/$22.49.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an electric vehicle ("EV") manufacturer, has received approval from the Massachusetts Executive Office of Energy and Environmental Affairs' Department of Energy Resources ("DOER") for its Mullen THREE to qualify for the state's $15,000 cash rebate voucher program. An all-electric Class 3 low cab forward truck, the Mullen THREE has a suggested MSRP of $68,500; however, when the Massachusetts state cash rebate of up to $15,000 is combined with the available $7,500 federal tax credit, the net effective price of the Mullen THREE totals an estimated $46,000. The MOR-EV program focuses on making electric vehicles more affordable for Massachusetts residents, businesses and nonprofit organizations. "Massachusetts' $15,000 MOR-EV cash voucher on our 2024 Mullen THREE is another example of a great state-level incentive making our Class 3 electric truck even more affordable to meet cost of ownership requirements for fleet customers of all sizes," said Mullen Automotive CEO and chair David Michery in the press release.

To view the full press release, visit

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Tuesday's trading session at $2.83, even for the day, on 1,679,524 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.3565/$382.05.

Recent News

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF)

The QualityStocks Daily Newsletter would like to spotlightFathom Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF).

Drill program shows defined thick new copper zones, indicating the possibility of rapid and significant expansion

The drilling program is being conducted by American West Metals Limited

RC drilling will continue in the Storm area, testing geophysical targets to expand known mineralization and test potential new zones of mineralization

Reverse circulation ("RC") drilling that began earlier this year at Aston Bay Holdings' (TSX.V: BAY) (OTCQB: ATBHF) Nunavut-based Storm Copper Project has already produced exciting results. The company is reporting that immediate exploration success defined thick new copper zones and indicated the possibility of rapid and significant expansion (

Aston Bay Holdings Ltd. (TSX.V: BAY) (OTCQB: ATBHF) is a publicly traded Canadian minerals exploration company focused on exploring high-grade copper and gold deposits in North America. The company owns the Storm Copper Project and the Seal Zinc Deposit in Nunavut, Canada, and is currently exploring the Buckingham Gold Vein and critical metals prospects in central Virginia. Aston Bay is also in the advanced stages of negotiation on other properties with high-grade critical minerals potential in these areas.

The company believes in responsible exploration and carries out its work programs to the highest standards of social responsibility, environmental stewardship and health and safety. Aston Bay cares about leaving a net positive impact on the communities in which it works and engages with local representatives, Indigenous groups and government agencies to build respectful relationships through dialogue and collaborative processes. Depending on the stage of exploration, these efforts may include employment, contracting, training, community benefits and other agreements.

Aston Bay conducts exploration through safe, socially and environmentally responsible and sustainable work practices. The company embeds core values of health and safety throughout its operations by adhering to strict health and safety standards and practices that meet and/or exceed industry standards and government codes and regulations.

The company is headquartered in Toronto.


Storm Copper

The high-grade Storm Copper Deposit is located 112 kilometers south of the community of Resolute Bay, Nunavut, on western Somerset Island, just south of the past-producing Polaris Pb-Zn Mine. The property comprises 173 contiguous mining claims, including the Storm Copper and Seal Zinc projects, covering an area of approximately 541,795 acres.

The property has good access to established shipping lanes, and the landscape provides favorable conditions for development of roads and a protected deep-water port. Exploration is supported through excellent infrastructure in the nearby hamlet of Resolute Bay.

Aston Bay is partnered with American West Metals (ASX: AW1) at Storm. American West is responsible for all exploration expenditures, having aggressively advanced the project toward production and earned an 80% interest. This affords excellent optionality to the company’s shareholders, as Aston Bay is free carried with no required expenditures until the completion of a bankable feasibility study.

American West recently completed an Australian JORC-compliant Maiden Resource Estimate for Storm; the North American 43-101 compliant resource estimate is expected in Q1 2024. American West is cashed up and plans a multimillion-dollar resource expansion and new discovery drilling program for the summer of 2024.

The Buckingham County Gold Project

The gold-bearing system at the Buckingham County Gold Project in Virginia lies within a belt hosting past producing mines, current gold mines and advanced gold explorations, stretching through Georgia, the Carolinas, Virginia, Nova Scotia and Newfoundland.

Buckingham hosts a “Kirkland Lake-style” high grade gold vein returning values consistently over one ounce gold per ton and is underexplored both at depth and along almost one mile of strike length. These types of veins have excellent ESG qualities, as they are typically mined using a small footprint underground method, with gold extracted using simple and environmentally friendly gravity methods.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

A report from Acumen Research and Consulting, a global provider of market intelligence and consulting services, valued the global copper market at $304.1 billion in 2022 and forecast that it will reach a market size of $496.8 billion by 2032, growing at a CAGR of 5.1% over the forecast period.

The report identifies a growing demand for copper in the electronics industry, as well as an expanding copper supply due to increasing production from existing mines and the rising number of mine development projects in developing nations, as driving factors in the rising value of the copper market.

Management Team

Thomas Ullrich is CEO and Director of Aston Bay. He has over 30 years of experience in mineral exploration and geoscience. Before joining Aston Bay, he was Chief Geologist North America for Antofagasta Minerals plc, investigating copper potential through extensive property evaluations and management of drill programs in the United States, Mexico and Canada. Prior to that, he was Senior Geologist for Almaden Minerals.

Sofia Harquail handles Investor Relations and Corporate Development at Aston Bay. She has over 15 years of experience in the private and public sectors of the mining industry. Before joining Aston Bay, she worked as a consultant for the Prospectors and Developers Association of Canada and for exempt market dealer Red Cloud Financial Services Inc. Ms. Harquail holds an M.A. from the University of Uppsala in Sweden and received her CPIR designation from the CIRI/Ivey Investor Relations Program. She also sits on the board of the Young Mining Professionals Toronto and is CSC Certified.

Aston Bay has a talented Board of Directors bringing broad experience from across the industry, encompassing resource expansion, mine development, mergers and acquisitions, and mining finance.

Ms. Jessie Liu-Ernsting has over 15 years of experience in the mining industry, spanning capital projects engineering, debt capital markets, private equity and corporate strategy at several firms, including Hudbay Minerals and Resource Capital Funds. She is currently VP Investor Relations and Communications at G Mining Ventures Corp.

Mr. Jeffrey R. Wilson has over 25 years’ experience in the mining industry, having served as a director, officer and advisor of multiple public and private companies in the mineral exploration and mining investment industries. Mr. Wilson is currently President & CEO of Precipitate Gold Corp.

Mr. Gary O’Connor has over 40 years of diverse experience as a mineral exploration and development professional in the management of successful resource projects as well as the evaluation, technical due diligence, and supervision of large mineral exploration and development projects through-out the world. While with Freeport, Mr. O’Connor worked on the due diligence and discovery of a major gold fraud on the Busang gold “deposit” in Kalimantan by Bre-X.

Mr. Mark J. Pryor is a geologist with a 40-year track record of successfully advancing multiple precious metal, copper, coal, REE and Li projects from discovery through to exploitation. He is currently Executive Vice President of the Exploration Division at The Electrum Group.

Aston Bay Holdings Ltd. (OTCQB: ATBHF), closed Tuesday's trading session at $0.0783, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0256/$0.2474.

Recent News

Longeveron Inc. (NASDAQ: LGVN)

The QualityStocks Daily Newsletter would like to spotlight Longeveron Inc. (NASDAQ: LGVN) .

Longeveron (NASDAQ: LGVN), a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, is participating in this week's Emerging Growth Virtual Conference. The agenda for the event indicates Longeveron CEO and director Mohamed Wa'el Hashad will be speaking tomorrow at 1:45 p.m. ET; the two-day conference is slated for June 12–13. In addition, Longeveron has successfully completed an investigator meeting for ELPIS II, the ongoing phase 2b clinical trial that is designed to evaluate LGVN's Lomecel-B(TM) as a potential adjunct treatment for hypoplastic left heart syndrome ("HLHS"). According to the announcement, the meeting included principal investigators and site staff from premiere infant and children's treatment institutions across the country and included discussion regarding progress to date and operational implementation of the clinical trial. Multiple nationally recognized children's treatment centers are participating in the ELPIS II study. HLHS is a rare pediatric congenital heart birth defect; with current HLHS treatment, only 50–60% of infants survive to adolescence. "We believe the data generated to date in HLHS support potential for Lomecel-B as a regenerative medical therapy to help these infants," said Longeveron chief medical officer Nataliya Agafonova, MD, in the press release. "In the ELPIS I phase 1 clinical trial, participating infants experienced 100% transplant-free survival up to five years of age after receiving Lomecel-B compared to approximate 20% mortality rate observed from historical control data. ELPIS II is designed to further our understanding of Lomecel-B's™ safety and efficacy in this patient population. With the collaboration of our outstanding investigative sites, we remain on track to complete enrollment of the clinical trial by the end of this year."

To view the Emerging Growth presentation, visit

To view the full press releases, visit and

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. The Company’s research and therapies are aimed at improving the outcome of infants born with a life-threatening heart condition, as well as improving the healthspan for the aging population – the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging, with function and ability to perform activities of daily living.

Longeveron is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.

The Company’s philosophy revolves around the idea that regenerative medicine may hold the potential to improve certain rare medical conditions and contribute to healthy aging. While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging.

Longeveron’s lead investigational product is Lomecel-B™, an allogeneic Medicinal Signaling Cell therapy product isolated from the bone marrow of young, healthy adult donors. As humans age, they experience a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation, and other issues. Clinical data has suggested that Lomecel-B™ may address these conditions through multiple mechanisms of action (MOA) that simultaneously target key aging-related processes.

The Company is headquartered in Miami, Florida.


Lomecel-B™ is being evaluated in multiple clinical trials for aging-related chronic diseases and other life-threatening conditions under U.S. FDA-approved Investigational New Drug applications. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas.

The drug is made from special living cells called Medicinal Signaling Cells (MSCs) that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45. Once the MSCs have been isolated from the fresh bone marrow through a careful selection process, the cells are culture-expanded (allowed to replicate under controlled laboratory conditions) into the billions using specialized techniques and processes. After a specific number of expansion cycles, called “passages,” the cells are harvested, separated into specific doses (e.g., 50 million cells), and cryopreserved until future use.

These cells have been shown to have characteristics that allow them to be transplanted from a donor to host without triggering a harmful immune response in the recipient, and they can be administered on an outpatient basis in as little as 40 minutes after thawing. Because of these characteristics, Lomecel-B™ is considered an “off-the-shelf” product.

In some trials, such as for Alzheimer’s disease and Aging-related Frailty, Lomecel-B™ is administered via peripheral intravenous infusion, while, in the Company’s HLHS trial, Lomecel-B™ is administered via direct injection into the heart tissue.

Market Opportunity

Longeveron estimates the potential market size for Lomecel-B™ in the treatment of HLHS to be up to $1 billion annually, globally.

U.S. patients suffering from Aging-related Frailty are estimated using U.S. Census Bureau statistics to be approximately 8.1 million. That population potentially represents a market for Lomecel-B™ of between $4 billion and $8 billion globally per year, according to Company estimates.

Additionally, the Alzheimer’s Association puts the number of Americans with that disease at 5.1 million, highlighting another potentially addressable market for Lomecel-B™, that’s worth $5 billion to $10 billion annually.

Management Team

Wa’el Hashad is CEO of Longeveron. He has more than 35 years of experience in the pharmaceutical and biotech industries. He has launched several successful brands in the U.S. and worldwide markets. Prior to joining Longeveron, he was president and CEO of Avanir Pharmaceuticals. Before Avanir, he was the chief commercial officer of Seres Therapeutics. He also has held senior leadership positions at Amgen, Boehringer Ingelheim, and Eli Lilly and Company. He holds a bachelor’s degree in pharmacy from Cairo University and an MBA from the University of Akron.

Joshua M. Hare, M.D., FACC, FAHA, is Co-Founder, Chief Science Officer and Chairman of Longeveron. He is a double board-certified cardiologist and is the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. He is a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award and is an elected member of the American Association of Physicians and The American Society for Clinical Investigation. He is also an elected Fellow of the American Heart Association. He received a bachelor’s degree from the University of Pennsylvania and his M.D. from The Johns Hopkins University School of Medicine.

Lisa Locklear is CFO at Longeveron. She previously served as the senior vice president and CFO for Avanir Pharmaceuticals. Prior to Avanir, she held senior financial roles at GSN Games, CoreLogic, Ingram Micro, the Walt Disney Company, and Price Waterhouse, with assignments in Paris and London. She holds a bachelor’s degree in plant science from the University of California, Davis, and an MBA from the University of California, Irvine. She is a licensed CPA (inactive) and is a member of the American Institute of Certified Public Accountants, the California Society of CPAs, and Financial Executives International.

Dr. Nataliya Agafonova, M.D., is the Chief Medical Officer at Longeveron. She previously served as clinical development lead, senior medical director, and product development chair at Otsuka Pharmaceuticals. Before that, she was the clinical development lead and senior medical director at Bristol-Myers Squibb. She previously held senior leadership positions at Ardea Bioscience, Biogen, Amgen, and Genzyme Corporation. She earned an M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the Company’s product candidates, and other positive results; the timing and focus of the Company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306

Date prepared: August 31, 2023

Longeveron Inc. (NASDAQ: LGVN), closed Tuesday's trading session at $0.82, off by 22.6415%, on 1,465,261 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.7707/$40.00.

Recent News

SenesTech Inc. (NASDAQ: SNES)

The QualityStocks Daily Newsletter would like to spotlight SenesTech Inc. (NASDAQ: SNES).

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, is scheduled to present at the 72nd Emerging Growth Conference, hosted by leading independent small cap media portal Taking place on June 12 - 13, 2024, the event identifies companies in a wide range of growth sectors with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth. Joel L. Fruendt, president, CEO and director of SenesTech is scheduled to provide a keynote speech at the conference starting at 3:20 p.m. ET on June 12.

To view the full press release, visit

SenesTech Inc. (NASDAQ: SNES) is the rodent fertility control expert and the inventor of the only EPA-registered contraceptive for male and female rats. The company’s technology provides an innovative and humane method for managing rat populations.

SenesTech is focused on developing effective solutions that are grounded in science and proven through research, all while providing value to people, communities and the environment. The company’s passion is to create a healthier world by better controlling rat pest populations. This aim is critical, as, if left unchecked, a breeding pair of rats and their descendants can produce up to 15,000 pups after just one year.

The company strives for clean cities, efficient businesses and happy households – with a product that was scientifically designed to be effective without killing rats. SenesTech is committed to the sustainable, humane treatment of animals, improving the quality of all human life and enhancing environmental stewardship through the global application of its effective solution in fertility control technology.

SenesTech is headquartered in Phoenix, Arizona.


SenesTech’s first product, ContraPest®, applies revolutionary technology to a global challenge that has persisted since the Middle Ages – the proliferation of rats in urban and agricultural settings. ContraPest® targets the reproductive capabilities of Norway and roof rats. As a highly palatable liquid, the formulation promotes sustained consumption, helping to reduce fertility in both male and female rats, bringing populations down and keeping them down.

The company’s flagship offering can be used as part of integrated pest management (IPM) programs – fitting seamlessly into all IPM programs – to help reduce reproduction and magnify the success of these protocols, or as a standalone solution for customers who want to reduce or eliminate the use of lethal rodent control methods.

In multiple, independent field deployments, ContraPest was shown to reduce rat activity over 90% when added to an existing IPM program.

ContraPest® is registered federally as a General Use Product.

Delivery Systems and New Products

In July 2023, SenesTech began to distribute a new delivery system for ContraPest®, the Isolate Bait System™. This new delivery system brings to market a simple design that enables more efficient deployment, incorporates an enhanced formulation of ContraPest® that is expected to provide improved performance of the fertility control bait in the field and is paired with a new bait station that is more space-efficient and economical.

The other delivery systems available for ContraPest include the Ultimate Bait System™, a tank and tray in a larger format for use with more severe infestations, and the Elevate Bait System™, a unique delivery system that targets above ground infestations, as with roof rats.

SenesTech, as of August 2023, is also in the final stages of releasing a soft bait formulation, which provides the unique attributes of proven fertility control in an industry-familiar format demanded by big box retailers, key e-commerce channels and leading industry pest management professionals.

Market Opportunity

According to SenesTech’s figures, rats cause over $27 billion in damage to public and private infrastructure annually in the United States. Rats also destroy 20% of the global stored food supply every year by consuming or contaminating it.

Rats are known to spread at least 35 diseases, globally posing a dangerous risk to public health and safety. Not only does this age-old problem persist despite extensive campaigns to eradicate it, but multiple sources have reported that post-COVID rat populations have boomed.

Poison-based control methods sicken rats, and they typically die slowly. An animal that eats a poisoned rat may also sicken or die. The global rodenticide market is projected to be worth $1.7 billion by 2026.

In one case study, results reported by the customer showed a $5,000 investment in ContraPest® saved more than $500,000 annually in reduced labor, loss and damage.

Management Team

Joel Fruendt is SenesTech’s President and CEO. He has 15 years of executive leadership in the vector and pest control industries as Vice President and General Manager of Clarke Environmental Inc., a leading vector and pest control products and services company. He has extensive expertise in the development and manufacturing of EPA-registered chemical control products, and the commercialization and sale of those products. He received the ‘Smart Leaders’ award from Smart Business Magazine and holds a bachelor’s degree in business from Illinois Wesleyan University.

Tom Chesterman is CFO at SenesTech. He has over 20 years of experience as the CFO of public companies in the life science, tech and telecommunications industries. Most recently, he was the Vice President and Treasurer of GCI, a telecommunications company. Previous to that, he was the CFO of life science companies Bio-Rad Laboratories, Aradigm and Bionovo. He has a bachelor’s degree from Harvard University and an MBA from the University of California at Davis.

Dan Palasky is Chief Technical Officer at SenesTech. Previously he held the title of Vice President of Research & Development at PLZ Corp., a manufacturer of chemical consumer products, serving as the technical expert for its entire product portfolio. He started his career with Camie-Campbell, Inc., as a chemist in the R&D department. Mr. Palasky received his bachelor’s degree in chemical engineering from the Missouri University of Science & Technology and his MBA in Project Management from Aspen University.

SenesTech Inc. (NASDAQ: SNES), closed Tuesday's trading session at $0.6986, off by 1.564%, on 28,646 volume. The average volume for the last 3 months is 111,653 and the stock's 52-week low/high is $0.52/$16.08.

Recent News

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene (NASDAQ: CLNN) is scheduled to present at the 72nd Emerging Growth Conference, hosted by leading independent small cap media portal Taking place on June 12 - 13, 2024, the event identifies companies in a wide range of growth sectors with strong management teams, innovative products and services, focused strategy, execution, and the overall potential for long-term growth. Clene's President and CEO Rob Etherington and CFO Morgan Brown will provide a keynote speech at the conference starting at 2:20 p.m. ET on June 12.

To view the full press release, visit

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.


CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Tuesday's trading session at $0.4144, off by 4.0741%, on 661,053 volume. The average volume for the last 3 months is 848,142 and the stock's 52-week low/high is $0.25/$1.09.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, will be featured in this week's Emerging Growth Conference. The conference is slated for June 12–13, 2024. According to the announcement, InMed Pharmaceuticals CEO Eric A. Adams will be presenting at the two-day event. During his presentation, Adams will provide a corporate overview of the company; the presentation will also include a Q&A session. Adams' presentation is scheduled to begin at 1:45 p.m. EDT on June 13. An archived replay of the presentation will be available on the InMed Pharmaceuticals website. The Emerging Growth conference is designed to provide an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office and in a time-efficient manner.

To view the presentation, visit

To view the full press release, visit

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.


The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Tuesday's trading session at $0.239, off by 3.278%, on 232,863 volume. The average volume for the last 3 months is 618,038 and the stock's 52-week low/high is $0.2151/$2.08.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.